Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models

Based on the author's recent experience, there appears to be some confusion regarding the steps required to qualify a systems pharmacology model as adequate for the intended purpose. This manuscript outlines the model evaluation approach used in the author's recent publication1 on the systems pharmacology of a 5‐lipoxygenase inhibitor and is an attempt to generate discussion on this topic within the pharmacometrics and systems pharmacology community.

[1]  B. Hendriks.  Negative Modeling Results: A Dime a Dozen or a Stepping Stone to Scientific Discovery? , 2013, CPT: pharmacometrics & systems pharmacology.

[2]  M. Riggs,et al.  Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model , 2012, CPT: pharmacometrics & systems pharmacology.

[3]  G. Cedersund,et al.  Putting the pieces together in diabetes research: towards a hierarchical model of whole-body glucose homeostasis. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  O Demin,et al.  Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic-Pharmacodynamic Behavior: An Example Using 5-Lipoxygenase Inhibitors , 2013, CPT: pharmacometrics & systems pharmacology.

[5]  N. Dubin.  Mathematical Model , 2022 .

[6]  Gunnar Cedersund,et al.  Insulin Signaling in Type 2 Diabetes , 2013, The Journal of Biological Chemistry.

[7]  Yongwimon Lenbury,et al.  Bariatric surgery and T2DM improvement mechanisms: a mathematical model , 2012, Theoretical Biology and Medical Modelling.

[8]  Gunnar Cedersund,et al.  A Hierarchical Whole-body Modeling Approach Elucidates the Link between in Vitro Insulin Signaling and in Vivo Glucose Homeostasis* , 2011, The Journal of Biological Chemistry.

[9]  W. Jusko,et al.  Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. , 2012, British journal of clinical pharmacology.